Everest Medicines, a biopharmaceutical company focused on innovative medicines and vaccines, recently announced key appointments to its management team. Ms. Sandra Zeng, with more than 20 years of experience in oncology and immunology, has been named Chief Medical Officer. She will lead clinical development efforts to bring innovative products to China. Mr. Rico Liang, with over two decades in the pharmaceutical industry, has been appointed Chief Product Officer, overseeing medical affairs and marketing departments.
The company’s CEO, Rogers Yongqing Luo, highlighted the importance of the new appointments in advancing Everest’s leading positions in renal, infectious, and autoimmune diseases. The strategic growth goals of Everest Medicines will benefit from the global and China experience brought by Ms. Zeng and Mr. Liang. They will facilitate integration between discovery, clinical development, medical affairs, and marketing to drive successful commercialization of products and long-term value creation.
Everest Medicines is committed to addressing critical unmet medical needs in Asian markets through transformative pharmaceutical products and vaccines. With a seasoned management team from leading global pharmaceutical companies, the company focuses on developing potentially first-in-class or best-in-class molecules in therapeutic areas including renal diseases, autoimmune disorders, and infectious diseases.
This announcement marks a significant step for Everest Medicines in strengthening its leadership team to drive innovation and commercialization efforts. The company’s dedication to advancing healthcare solutions and creating long-term value for patients underscores its commitment to making a meaningful impact in the biopharmaceutical industry.
For more information about Everest Medicines and its portfolio of innovative products, visit their website at http://www.everestmedicines.com. Stay tuned for future updates as the company continues to make strides in transforming the healthcare landscape with cutting-edge pharmaceuticals and vaccines.
Source link
